Company intelligence / Profile preview

Exosomics

Siena, Tuscany, Italy

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Exosomics has launched commercially available exosome enrichment kits for research use and is developing a clinical-grade early pan-cancer screening test. Scientific validation indicates improved sensitivity and specificity over traditional liquid biopsies, but published clinical trial results for the pan-cancer screening test are not yet available.

Therapeutic areas: Oncology
Modalities: Exosome-based liquid biopsyDeviceExosome-based therapy
Industry: Molecular Diagnostics

Partnerships

NanoFCM (instrumentation/service partnership)Lonza (minority shareholder, service unit acquisition, strategic support)

Beyond the preview

Go deeper on Exosomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exosomics.

Explore the full profile